Quince Therapeutics' Clinical Trial Fails, Stock Drops Significantly
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 29 Jan 26
Quince Therapeutics Inc's stock plummeted after the company announced that its NEAT clinical trial failed to meet its primary endpoint, resulting in a significant price drop.
The NEAT trial's results showed a mean change of 0.94 in the active arm compared to 2.24 in the placebo arm, with a p-value of 0.0851, indicating limited treatment efficacy. Additionally, the trial did not meet its key secondary endpoint, leading the company to halt the development of eDSP to preserve cash and reassess its market strategy.
This failure highlights the challenges in developing effective treatments for rare diseases like Ataxia-Telangiectasia, which may impact Quince's future R&D investments and overall market position.
Analyst Views on QNCX
Wall Street analysts forecast QNCX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QNCX is 7.00 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.180
Low
5.00
Averages
7.00
High
10.00
Current: 3.180
Low
5.00
Averages
7.00
High
10.00
About QNCX
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
